| Literature DB >> 32349835 |
Julien Dubreucq1,2,3,4, Franck Gabayet2,3, Bernard Ycart5, Megane Faraldo2,3, Fanny Melis2, Thierry Lucas2, Benjamin Arnaud6, Mickael Bacconnier7,8, Motassem Bakri8, Gentiane Cambier9, Florian Carmona10, Isabelle Chereau3,11, Titaua Challe12, Sophie Morel8, Sylvie Pires3,11, Celine Roussel12, Philippe Lamy10, Guillaume Legrand6, Emmanuelle Pages9, Romain Pommier10, Romain Rey3,13, Yohan Souchet3,13, Pierre-Michel Llorca3,11, Catherine Massoubre10.
Abstract
BACKGROUND: Functional capacity (FC) has been identified as a key outcome to improve real-world functioning in schizophrenia. FC is influenced by cognitive impairments, negative symptoms, self-stigma and reduced physical activity (PA). Psychosocial interventions targeting FC are still under-developed.Entities:
Keywords: Physical activity; schizophrenia; social cognitive remediation; social function; touchrugby
Mesh:
Year: 2020 PMID: 32349835 PMCID: PMC7355162 DOI: 10.1192/j.eurpsy.2020.42
Source DB: PubMed Journal: Eur Psychiatry ISSN: 0924-9338 Impact factor: 5.361
Baseline characteristics in the RR and the TR groups
| RR ( | TR ( | Welsh two-sample | |||||
|---|---|---|---|---|---|---|---|
| Variable |
|
|
|
|
|
| PV |
| Age | 33.3 | 8.8 | 33.1 | 7.9 | 0.1 | 65.3 | 0.901 |
| Education | 11.3 | 2.3 | 10.7 | 2 | 1.3 | 65.2 | 0.199 |
| Participation | 0.9 | 0.1 | 0.9 | 0.1 | −1.7 | 55.4 | |
| PANSS.Tot | 76.1 | 15.3 | 68.2 | 14.7 | 2.3 | 58.3 | |
| PANSS.Pos | 15.7 | 4.7 | 14.8 | 4.5 | 0.8 | 58.5 | 0.428 |
| PANSS.Neg | 23.4 | 6.1 | 19.4 | 5.7 | 3 | 59.8 | |
| PANSS.GP | 37.3 | 8.1 | 33.9 | 8.7 | 1.7 | 52.9 | |
| PSP | 55.9 | 12.4 | 54.9 | 16.2 | 0.3 | 45.2 | 0.765 |
| ERF-CS.Tot | 48.2 | 25.8 | 48.2 | 34.2 | 0 | 41.2 | 0.996 |
| Simil.NB | 20.2 | 5.6 | 19.8 | 5.9 | 0.3 | 56.9 | 0.793 |
| BEMRI.NB | 5.9 | 2.5 | 5.8 | 2.8 | 0.2 | 52.9 | 0.862 |
| BEMRD.NB | 5.4 | 2.7 | 5.6 | 3 | −0.3 | 54.2 | 0.746 |
| TMTA.Time | 41.8 | 16.4 | 45.5 | 24 | −0.7 | 44 | 0.459 |
| TMTB.Time | 114.9 | 67.8 | 136.7 | 94.4 | −1.1 | 43.4 | 0.274 |
| Coding.NB | 50.7 | 13.1 | 51.8 | 14.8 | −0.3 | 53.5 | 0.732 |
| PerSo.Tot | 21.4 | 4.4 | 19.7 | 4.3 | 1.7 | 61.3 | 0.09 |
| Shopping.time | 5.8 | 3.3 | 7.1 | 5.3 | −1.2 | 41.6 | 0.226 |
| MASC.CM | 22 | 7.3 | 22.7 | 8.4 | −0.4 | 51 | 0.717 |
| MASC.Hy | 6.2 | 3.5 | 7.6 | 2.9 | −2 | 67.9 | |
| MASC.Ho | 11.6 | 5.3 | 10.1 | 4.8 | 1.2 | 62.1 | 0.224 |
| MASC.Abs | 5.3 | 3.5 | 4.6 | 3 | 1 | 65.2 | 0.338 |
| f.NART | 99.8 | 8.5 | 100.2 | 9.2 | −0.2 | 55.5 | 0.861 |
| ACSo.Tot | 31.8 | 9.5 | 31.5 | 8.2 | 0.2 | 67.3 | 0.872 |
| SERS.posit | 41.6 | 10.4 | 40.9 | 12.2 | 0.3 | 52.3 | 0.788 |
| SERS.negat | 34.1 | 10.1 | 37.4 | 12.9 | −1.2 | 49.1 | 0.243 |
| QCAE.tot | 83.6 | 9.8 | 84.5 | 8.9 | −0.4 | 64.4 | 0.657 |
| ISMI.Tot | 2.3 | 0.4 | 2.3 | 0.6 | −0.4 | 42.3 | 0.69 |
| ISMI.Alien | 2.5 | 0.7 | 2.6 | 0.9 | −0.7 | 47.6 | 0.471 |
| ISMI.Stereo | 2.1 | 0.5 | 2 | 0.7 | 0.3 | 46.7 | 0.75 |
| ISMI.Discri | 2.3 | 0.6 | 2.4 | 0.9 | −0.5 | 43 | 0.635 |
| ISMI.Rsoc | 2.4 | 0.6 | 2.5 | 0.8 | −0.5 | 48.9 | 0.605 |
| ISMI.Rstig | 2.3 | 0.5 | 2.3 | 0.5 | 0.2 | 58.5 | 0.847 |
| AIHQ.Host | 1.8 | 0.8 | 1.9 | 0.6 | −0.9 | 69.3 | 0.351 |
| AIHQ.Intent | 3 | 1.1 | 3.2 | 1.1 | −0.6 | 59.1 | 0.529 |
| AIHQ.Anger | 2.8 | 1.2 | 3.2 | 1.1 | −1.2 | 58.3 | 0.238 |
| AIHQ.Blame | 3.2 | 1.2 | 3.3 | 1.1 | −0.4 | 62.9 | 0.7 |
| AIHQ.Agres | 1.5 | 0.5 | 1.6 | 0.4 | −0.6 | 72.3 | 0.519 |
| AIHQ.AttRe | 3 | 1 | 3.2 | 1 | −0.8 | 58.2 | 0.42 |
| STORI.Mora | 19.4 | 8.4 | 19.5 | 9.8 | 0 | 50.1 | 0.963 |
| STORI.Cons | 26.9 | 9.9 | 27.2 | 11.9 | −0.1 | 48.6 | 0.907 |
| STORI.Prep | 29.2 | 9.2 | 29.9 | 8.8 | −0.3 | 59.6 | 0.732 |
| STORI.Reco | 31 | 8.5 | 34.8 | 9.2 | −1.9 | 53.3 | 0.069 |
| STORI.Croi | 31 | 9 | 34.3 | 10 | −1.5 | 52 | 0.14 |
| BUES.Tot | 2.2 | 0.3 | 2.1 | 0.3 | 0.7 | 47 | 0.458 |
| CPZ.EQ | 6 | 2.9 | 5.5 | 3.5 | 0.7 | 49.9 | 0.493 |
For each of the 42 outcome variables, the table displays the sample mean and standard deviation of the variable over the Expe patients, then over the TR patients, then the results (test statistic, degrees of freedom, p value) of the Walsh two-sample two-sided T test between both. A p value smaller than 0.05 indicates that the difference of means is significant. CPZ100eq: dose equivalent to 100 mg/day of chlorpromazine calculated according to the minimum effective dose method [25]. The mean antipsychotic dose in the sample was equivalent to 6 mg/day chlorpromazine in the RR group and to 5.5 in the TR group.
Abbreviations: AcSo, self-assessment of social cognition; AIHQ, Ambiguous Intentions and Hostility Questionnaire (agress, aggression bias; anger, anger score; blame, blame score; host, hostility bias; resp, attribution of responsibility); BUES, Boston University Empowerment Scale; BEM-RI, BEM immediate recall; BEM-RD, BEM delayed recall; Coding, WAIS-IV Coding subscale; Education, Education level (years); ERF-CS, Social Cognition—Functional Outcomes Scale; ISMI, Internalized Stigma of Mental Illness scale (tot, total score; Alien, alienation subscale; stereo, stereotype endorsement; discri, discrimination experience; soc-with, social withdrawal; Rstig, stigma resistance); MASC, Movie for the Assessment of Social Cognition (Abs, absence of ToM; CM, correct mentalization score; Ho, hypomentalization; Hy, hypermentalization score); PANSS, Positive and Negative Syndrome Scale (positive, negative, and general psychopathology subscales); PerSo, social perception test; PSP, Personal and Social Performance Scale total score; QCAE, Questionnaire of Cognitive and Affective Empathy; SERS-SF, Self-Esteem Rating Scale-short form (positive and negative subscales); Simil NB, WAIS IV Similarities subtest; STORI, stage of recovery instrument (awar, awareness; growth, growth stage; mora, moratorium stage; prep, preparation stage; rebuil, rebuilding stage); TMT, Trail Making Test A and B; Bold values indicate the p-values significant at p<0.05.
Figure 1.Overview of the RemedRugby topics.
Improvements in the RemedRugby group at post-treatment and follow-up
| Baseline post-treatment | Baseline follow-up | Post-treatment follow-up | |
|---|---|---|---|
| PANSS.Tot | |||
| PANSS.Pos | 0.101 | ||
| PANSS.Neg | |||
| PANSS.GP | |||
| PSP | |||
| ERFCS.Tot | 0.181 | ||
| Simil.NB | |||
| BEMRI.NB | 0.158 | ||
| BEMRD.NB | |||
| TMTA.Time | |||
| TMTB.Time | |||
| Coding.NB | |||
| PerSo.Tot | 0.306 | 0.264 | |
| Shopping.time | 0.178 | 0.142 | 0.257 |
| MASC.MC | 0.113 | ||
| MASC.Hy | 0.07 | 0.119 | 0.32 |
| MASC.Ho | 0.689 | 0.05 | |
| MASC.Abs | 0.06 | 0.5 | |
| f.NART | 0.052 | 0.053 | |
| ACSo.Tot | 0.176 | 0.227 | 0.261 |
| SERS.posit | 0.308 | 0.735 | |
| SERS.negat | 0.294 | ||
| QCAE.tot | 0.492 | 0.318 | 0.206 |
| ISMI.Tot | 0.981 | ||
| ISMI.Alien | 0.107 | 0.079 | 0.398 |
| ISMI.Stereo | 0.999 | ||
| ISMI.Discri | 0.124 | 0.812 | |
| ISMI.Socwith | 0.213 | 0.988 | |
| ISMI.Rstig | 0.953 | 0.495 | 0.36 |
| AIHQ.Host | 0.148 | 0.07 | |
| AIHQ.Intent | 0.428 | 0.339 | 0.89 |
| AIHQ.Anger | 0.152 | 0.288 | 0.744 |
| AIHQ.Blame | 0.228 | 0.135 | 0.828 |
| AIHQ.Agres | 0.098 | 0.718 | |
| AIHQ.AttRe | 0.236 | 0.193 | 0.89 |
| STORI.Mora | 0.368 | 0.13 | |
| STORI.Awar | 0.657 | 0.28 | 0.152 |
| STORI.Prep | 0.479 | 0.797 | 0.904 |
| STORI.Rebuild | 0.335 | 0.119 | 0.226 |
| STORI.Growth | 0.127 | 0.341 | |
| BUES.Tot | 0.654 | 0.969 | 0.633 |
| CPZ.EQ | 0.082 |
For each of the 42 outcomes variable, the table displays the p values of three Walsh paired samples one-sided T tests: values at V1 against V2, then V2 against V3, then V1 against V3. In each case, the alternative has been chosen so that a small p value should correspond to improvement of the patient’s condition between consecutive visits. CPZ100eq: dose equivalent to 100 mg/day of chlorpromazine calculated according to the minimum effective dose method [49].
Abbreviations: AcSo, self-assessment of social cognition; AIHQ, Ambiguous Intentions and Hostility Questionnaire (agress, aggression bias; anger, anger score; blame, blame score; host, hostility bias; resp, attribution of responsibility); BEM-RD, BEM delayed recall; BEM-RI, BEM immediate recall; BUES, Boston University Empowerment Scale; Coding, WAIS-IV Coding subscale; Education, education level (years); ERF-CS, Social Cognition—Functional Outcomes Scale; ISMI, Internalized Stigma of Mental Illness scale (Alien, alienation subscale; discri, discrimination experience; Rstig, stigma resistance; stereo, stereotype endorsement; soc-with, social withdrawal; tot, total score); MASC, Movie for the Assessment of Social Cognition (Abs, absence of ToM; CM, correct mentalization score; Ho, hypomentalization; Hy, hypermentalization score); PANSS, Positive and Negative Syndrome Scale (positive, negative, and general psychopathology subscales); PerSo, social perception test; PSP, Personal and Social Performance Scale total score; QCAE, Questionnaire of Cognitive and Affective Empathy; SERS-SF, Self-Esteem Rating Scale-Short Form (positive and negative subscales); Simil NB, WAIS IV Similarities subtest; STORI, tage of recovery instrument (awar, awareness; growth, growth stage; mora, moratorium stage; prep, preparation stage; rebuil, rebuilding stage); TMT, Trail Making Test A and B; Bold values indicate the p-values significant at p<0.05.
Univariate differences between V1 and V2
| RR ( | TR ( | Welsh two-sample | ||||||
|---|---|---|---|---|---|---|---|---|
| Difference variable |
|
|
|
|
|
| PV | Cohen_d |
| PANSS.Tot | 3.7 | 12.1 | −7.2 | 9.8 | 4.4 | 65.1 | ||
| PANSS.Pos | 0.8 | 3.8 | −1.6 | 4.3 | 2.5 | 48.4 | ||
| PANSS.Neg | 1.2 | 4.4 | −2.4 | 4.1 | 3.7 | 58.9 | ||
| PANSS.GP | 1.8 | 5.5 | −3.5 | 5 | 4.4 | 60 | ||
| PSP | 4.4 | 9.3 | −8.3 | 11.5 | 5.1 | 48.1 | ||
| ERFCS.Tot | 2.2 | 18.5 | −4.1 | 15.9 | 1.6 | 60.6 | 0.061 | 0.357 |
| Simil.NB | 0.6 | 2.8 | −1 | 2.6 | 2.5 | 64.5 | ||
| BEMRI.NB | −0.1 | 1.5 | 0.2 | 1.9 | −0.9 | 49.8 | 0.823 | −0.229 |
| BEMRD.NB | −0.1 | 1.7 | 0.1 | 2 | −0.4 | 54.8 | 0.647 | −0.090 |
| TMTA.Time | 0.9 | 8 | −1.5 | 16.4 | 0.8 | 37.3 | 0.226 | 0.206 |
| TMTB.Time | −2.6 | 38.3 | 4.7 | 33 | −0.9 | 63.1 | 0.808 | −0.197 |
| Coding.NB | −0.3 | 7.6 | 0.6 | 6 | −0.6 | 72.2 | 0.73 | −0.134 |
| PerSo.Tot | 0.5 | 4.2 | −0.8 | 4.7 | 1.3 | 55.5 | 0.1 | 0.309 |
| Shopping.time | −0.1 | 2.7 | 0.3 | 2.4 | −0.7 | 68 | 0.755 | −0.154 |
| MASC.MC | −0.1 | 4.1 | 0.1 | 4.6 | −0.2 | 53.3 | 0.587 | −0.053 |
| MASC.Hy | 0.2 | 2.3 | −0.3 | 3.2 | 0.8 | 44.3 | 0.214 | 0.205 |
| MASC.Ho | −0.4 | 3.4 | 0.8 | 3.5 | −1.5 | 56.2 | 0.934 | −0.360 |
| MASC.Abs | 0.2 | 2.1 | −0.3 | 2.8 | 0.8 | 46.3 | 0.216 | 0.199 |
| f.NART | 0.2 | 4.4 | −0.3 | 4.9 | 0.5 | 55.3 | 0.315 | 0.115 |
| ACSo.Tot | 0.1 | 7.4 | −0.2 | 6.6 | 0.2 | 66.9 | 0.435 | 0.037 |
| SERS.posit | 0.5 | 9.1 | −0.7 | 9.2 | 0.6 | 61.6 | 0.286 | 0.133 |
| SERS.negat | −0.2 | 6.1 | 0.4 | 7.6 | −0.4 | 52.6 | 0.639 | −0.088 |
| QCAE.tot | −1.6 | 6.9 | 2.5 | 7.3 | −2.5 | 59.1 | 0.992 | −0.583 |
| ISMI.Tot | 0 | 0.3 | 0 | 0.3 | 1.1 | 64 | 0.141 | 0.250 |
| ISMI.Alien | −0.1 | 0.5 | 0.1 | 0.5 | −1.7 | 62.3 | 0.952 | −0.395 |
| ISMI.Stereo | 0.1 | 0.4 | −0.1 | 0.4 | 2.1 | 61.8 | ||
| ISMI.Discri | 0.1 | 0.5 | −0.1 | 0.4 | 1.7 | 66.5 | ||
| ISMI.Socwith | 0 | 0.5 | 0 | 0.4 | 0.4 | 73.8 | 0.343 | 0.088 |
| ISMI.Rstig | −0.1 | 0.3 | 0.1 | 0.5 | −1.4 | 46.4 | 0.918 | −0.358 |
| AIHQ.Host | 0 | 0.6 | −0.1 | 0.8 | 0.8 | 46.2 | 0.224 | 0.195 |
| AIHQ.Intent | 0.1 | 0.9 | −0.2 | 1.1 | 1.4 | 51.7 | 0.087 | 0.339 |
| AIHQ.Anger | 0 | 0.7 | −0.1 | 1.2 | 0.3 | 41.3 | 0.364 | 0.092 |
| AIHQ.Blame | 0.1 | 1 | −0.1 | 1.2 | 0.7 | 49.4 | 0.235 | 0.182 |
| AIHQ.Agres | 0.1 | 0.4 | −0.2 | 0.5 | 2.5 | 47.4 | 0.627 | |
| AIHQ.AttRe | 0.1 | 0.8 | −0.1 | 1 | 0.9 | 46.2 | 0.176 | 0.239 |
| STORI.Mora | −0.6 | 6.5 | 1 | 6.7 | −1 | 58 | 0.841 | 0.240 |
| STORI.Awar | 0.4 | 5.4 | −0.6 | 8 | 0.5 | 43.8 | 0.294 | 0.141 |
| STORI.Prep | −0.5 | 7.5 | 0.8 | 8.1 | −0.7 | 55.7 | 0.754 | 0.166 |
| STORI.Rebuild | −0.5 | 6.5 | 0.8 | 6 | −0.9 | 63 | 0.814 | 0.208 |
| STORI.Growth | −0.5 | 8.8 | 0.7 | 5.8 | −0.7 | 73.7 | 0.758 | −0.151 |
| BUES.Tot | 0 | 0.3 | −0.1 | 0.2 | 1.4 | 69.2 | 0.088 | 0.306 |
| CPZ.EQ | 0.1 | 0.8 | −0.1 | 0.3 | 1.8 | 79.6 | 0.317 | |
For each of the 42 outcome variables, improvement was defined as the difference between the value at V2 and V1, oriented so that a positive difference should correspond to an improvement of the patient’s condition. Each difference was adjusted by a linear regression over its confounding value at V1. The table displays the sample size mean and standard-deviation of the adjusted difference over the Expe patients, then over the TR patients, then the results (test statistic, degrees of freedom, p value) of the Walsh two-sample one-sided T test between both. A p value smaller than 0.05 indicates that the mean improvement over Expe patients is significantly higher. CPZ100eq: dose equivalent to 100 mg/day of chlorpromazine calculated according to the minimum effective dose method [49].
Abbreviations: AcSo, self-assessment of social cognition; AIHQ, Ambiguous Intentions and Hostility Questionnaire (agress, aggression bias; anger, anger score; blame, blame score; host, hostility bias; resp, attribution of responsibility); BEM-RD, BEM delayed recall; BEM-RI, BEM immediate recall; BUES, Boston University Empowerment Scale; Coding, WAIS-IV Coding subscale; Education, education level (years); ERF-CS, Social Cognition—Functional Outcomes Scale; ISMI, Internalized Stigma of Mental Illness scale (Alien, alienation subscale; discri, discrimination experience; Rstig, stigma resistance; stereo, stereotype endorsement; soc-with, social withdrawal; tot, total score); MASC, Movie for the Assessment of Social Cognition (Abs, absence of ToM; CM, correct mentalization score; Ho, hypomentalization; Hy, hypermentalization score); PANSS, Positive and Negative Syndrome Scale (positive, negative, and general psychopathology subscales); PerSo, social perception test; PSP, Personal and Social Performance Scale total score; QCAE, Questionnaire of Cognitive and Affective Empathy; SERS-SF, Self-Esteem Rating Scale-Short Form (positive and negative subscales); Simil NB, WAIS IV Similarities subtest; STORI, tage of recovery instrument (awar, awareness; growth, growth stage; mora, moratorium stage; prep, preparation stage; rebuil, rebuilding stage); TMT, Trail Making Test A and B; Bold values indicate the p-values significant at p<0.05.
Multivariate analysis
| PANSS.Tot | PANSS.Pos | PANSS.Neg | PANSS.GP | PSP | |
|---|---|---|---|---|---|
| expetau | |||||
| Age1 | 0.235 | 0.688 | 0.088 | 0.167 | 0.132 |
| Gender | 0.442 | 0.739 | 0.231 | 0.326 | 0.104 |
| Education | 0.114 | 0.15 | 0.532 | 0.946 | |
| Participation | 0.195 | 0.123 | 0.375 | ||
| PANSS.Tot1 | 0.501 | 0.433 | 0.785 | 0.422 | 0.971 |
| PANSS.Pos1 | 0.461 | 0.666 | 0.876 | 0.636 | 0.771 |
| PANSS.Neg1 | 0.632 | 0.452 | 0.916 | 0.622 | 0.847 |
| PANSS.GP1 | 0.385 | 0.424 | 0.557 | 0.318 | 0.901 |
| PSP1 | 0.896 | 0.031 | 0.34 | 0.205 | 0.741 |
| CPZ.EQ1 | 0.549 | 0.837 | 0.743 | 0.481 | 0.327 |
| 0.084 | 0.262 | 0.072 | 0.318 |
The table displays results of the multivariate analysis for the adjusted differences (improvement) of the four PANSS scores, and the PSP score, successively considered as response variables. Eleven potentially explanatory factors are considered. They include the exposure to the treatment, four descriptive variables, the values at V1 of the five variables of interest, and the level of treatment CPZ.EQ. The first 11 rows give the p value of the contribution to the complete linear model of each explanatory variable. On the last row, the p value of the two-way a nova of the simple linear regression against the full model is displayed.
Abbreviations: PANSS, Positive and Negative Syndrome Scale; PSP, Personal and Social Performance Scale; Bold values indicate the p-values significant at p<0.05.
Figure 2.CONSORT flow diagram.